Maggiore G, Bernard O, Hadchouel M, Hadchouel P, Odievre M, Alagille D
J Pediatr. 1984 Jun;104(6):839-44. doi: 10.1016/s0022-3476(84)80477-1.
Seventeen children with chronic active hepatitis and high serum titers of smooth-muscle or liver-kidney microsomal antibodies were given prednisone and azathioprine. Clinical and biochemical remission was obtained in all but two, who died of progressive liver failure. Evaluations in 14 children after a mean period of 22 months of treatment showed normal transaminase activity and gammaglobulin levels in 12, and serum autoantibody titers of less than 1: 100 in 10; liver histologic findings showed absence of inflammation in seven children, moderate portal or lobular inflammation in five, and minor features of aggressivity in two. Cessation of therapy was then attempted in nine children. Relapse occurred in all but one and could not be attributed to any previously recorded biologic or histologic feature. After follow-up of 18 months to 7 years, all but two patients are still receiving maintenance therapy with prednisone and azathioprine. Cirrhosis was present before treatment in 13 children and is now present in all but one. These results suggest that in most children with autoimmune chronic active hepatitis, immunosuppressive therapy can prevent further deterioration of liver function but must be pursued for several years before discontinuation is attempted.
17名患有慢性活动性肝炎且血清平滑肌或肝肾微粒体抗体滴度较高的儿童接受了泼尼松和硫唑嘌呤治疗。除两名死于进行性肝功能衰竭的儿童外,其他所有儿童均实现了临床和生化缓解。在平均治疗22个月后,对14名儿童进行评估,结果显示12名儿童的转氨酶活性和γ球蛋白水平正常,10名儿童的血清自身抗体滴度低于1:100;肝脏组织学检查结果显示,7名儿童无炎症,5名儿童有中度门静脉或小叶炎症,2名儿童有轻微侵袭性特征。随后,对9名儿童尝试停止治疗。除1名儿童外,其他儿童均复发,且复发无法归因于任何先前记录的生物学或组织学特征。在随访18个月至7年后,除两名患者外,所有患者仍在接受泼尼松和硫唑嘌呤维持治疗。13名儿童在治疗前就已出现肝硬化,现在除1名儿童外,其他儿童均有肝硬化。这些结果表明,对于大多数自身免疫性慢性活动性肝炎儿童,免疫抑制治疗可预防肝功能进一步恶化,但在尝试停药前必须持续治疗数年。